Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Fantini

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Oncotarget|November 19, 2016
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 alleleCaroline Jochems, James W Hodge, Massimo Fantini, et al.
Frontiers in Oncology|July 9, 2020
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian CancerKristen P Zeligs, Maria Pia Morelli, Justin M David, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|September 4, 2014
Phylogeny of Dengue and Chikungunya viruses in Al Hudayda governorate, YemenMassimo Ciccozzi, Alessandra Lo Presti, Eleonora Cella, et al.
Oncotarget|September 17, 2015
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeuticElizabeth S Gabitzsch, Kwong Yok Tsang, Claudia Palena, et al.
Oncotarget|May 19, 2016
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cellsCaroline Jochems, Massimo Fantini, Romaine I Fernando, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 29, 2023
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumorsChristopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 26, 2023
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumorsChristopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Oncotarget|November 19, 2016
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 alleleCaroline Jochems, James W Hodge, Massimo Fantini, et al.
Frontiers in Oncology|July 9, 2020
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian CancerKristen P Zeligs, Maria Pia Morelli, Justin M David, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|September 4, 2014
Phylogeny of Dengue and Chikungunya viruses in Al Hudayda governorate, YemenMassimo Ciccozzi, Alessandra Lo Presti, Eleonora Cella, et al.
Oncotarget|September 17, 2015
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeuticElizabeth S Gabitzsch, Kwong Yok Tsang, Claudia Palena, et al.
Oncotarget|May 19, 2016
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cellsCaroline Jochems, Massimo Fantini, Romaine I Fernando, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 29, 2023
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumorsChristopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 26, 2023
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumorsChristopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
Pageof 5